Valeant Will Add Salix To Roster | Chemical & Engineering News
Volume 93 Issue 9 | p. 16 | Concentrates
Issue Date: March 2, 2015

Valeant Will Add Salix To Roster

Department: Business
Keywords: specialty pharmaceutials, M&A, gastrointestinal

Specialty pharmaceuticals firm Valeant will pay $14.5 billion, including debt, to acquire Raleigh, N.C.-based Salix Pharmaceuticals. The deal, the largest in a series of purchases for Valeant, adds a portfolio of gastrointestinal treatments and an experienced sales team. Valeant expects to carve $500 million in annual costs out of the combined company by cutting R&D and corporate overhead. Salix’s specialty sales force and hospital reimbursement teams will be spared. Valeant operates with a minuscule R&D budget, focusing instead on growth through acquisition.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment